Brompheniramine (maleate)

980-71-2

C20H23BrN2O4

DMSO : >= 30 mg/mL (68.92 mM)

Immunology/Inflammation; GPCR/G Protein; Neuronal Signaling

Brompheniramine maleate is a histamine H1 receptors antagonist. Target: Histamine H1 Receptor Brompheniramine maleate, is an antihistamine drug of the propylamine (alkylamine) class. It is readily available over the counter and is indicated for the treatment of the symptoms of the common cold and allergic rhinitis. It is a first-generation antihistamine. Brompheniramine has antidepressant properties, inhibiting reuptake of the neurotransmitter serotonin. Based on this knowledge, Arvid Carlsson and his colleagues, working at the Swedish company Astra AB, were able to derive the first marketed selective serotonin reuptake inhibitor, zimelidine, from brompheniramine. Brompheniramine had a long half-life and large volume of distribution in normal adults. It also had a prolonged antihistaminic effect in the skin as evidenced by suppression of the wheal and flare response to histamine and by suppression of pruritus [1, 2].